NCT00695292View on ClinicalTrials.gov

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

September 30, 2012

Conditions
Small Cell Lung Cancer
Interventions
DRUG

irinotecan

irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15

DRUG

Carboplatin

carboplatin AUC=4 on Day 1

DRUG

sunitinib

sunitinib 25 mg orally (PO) daily after initial chemotherapy

Trial Locations (10)

20817

Center for Cancer and Blood Disorders, Bethesda

29303

Spartanburg Regional Medical Center, Spartanburg

30501

Northeast Georgia Medical Center, Gainesville

32804

Florida Hospital Cancer Insitute, Orlando

33901

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

45242

Oncology Hematology Care, Cincinnati

63017

St. Louis Cancer Care, Chesterfield

70806

Baton Rouge General Medical Center, Baton Rouge

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00695292 - Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter